Global Endowment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-5,200
Closed -$493K 139
2024
Q1
$493K Hold
5,200
0.05% 109
2023
Q4
$464K Hold
5,200
0.05% 111
2023
Q3
$380K Hold
5,200
0.04% 101
2023
Q2
$433K Hold
5,200
0.05% 65
2023
Q1
$396K Sell
5,200
-11,800
-69% -$979K 0.04% 86
2022
Q4
$1.41M Hold
17,000
0.16% 58
2022
Q3
$1.35M Hold
17,000
0.14% 60
2022
Q2
$1.26M Hold
17,000
0.11% 73
2022
Q1
$1.53M Buy
+17,000
New +$1.57M 0.11% 69

Other funds holding XBI

Global Endowment Management's XBI Position: Q2 2024 in Review

Global Endowment Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 5,200 shares — an estimated $493K sold.

Global Endowment Management first reported a position in XBI in Q1 2022 and held it in 9 quarters. The position peaked at $1.53M in Q1 2022. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

  • Global Endowment Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
  • Global Endowment Management sold 5,200 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $493K.
  • Global Endowment Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 9 quarters.
  • Global Endowment Management's State Street SPDR S&P Biotech ETF position peaked at $1.53M in Q1 2022.
  • 761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Global Endowment Management's 13F filing for Q2 2024, filed 13 Aug 2024.